1. Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study.
- Author
-
Guenther, Michael, Haas, Michael, Heinemann, Volker, Kruger, Stephan, Westphalen, Christoph Benedikt, von Bergwelt-Baildon, Michael, Mayerle, Julia, Werner, Jens, Kirchner, Thomas, Boeck, Stefan, and Ormanns, Steffen
- Subjects
PANCREATIC tumors ,LIPOPOLYSACCHARIDES ,ADENOCARCINOMA ,DISEASE progression ,RESEARCH ,CLINICAL trials ,IMMUNOHISTOCHEMISTRY ,RESEARCH methodology ,DEOXYCYTIDINE ,PROGNOSIS ,MEDICAL cooperation ,EVALUATION research ,TREATMENT effectiveness ,COMPARATIVE studies ,SURVIVAL analysis (Biometry) ,DRUG resistance in cancer cells ,MEDICAL research ,LONGITUDINAL method - Abstract
Background: Gram-negative bacteria mediated gemcitabine resistance in pre-clinical models. We determined if intratumoural lipopolysaccharide (LPS) detection by immunohistochemistry is associated with outcome in advanced pancreatic ductal adenocarcinoma (PDAC) treated with gemcitabine and non-gemcitabine containing 1st-line chemotherapy.Methods: We examined LPS on tumour tissue from 130 patients treated within the randomised AIO-PK0104 trial and a validation cohort (n = 113) and analysed the association of LPS detection to patient outcome according to treatment subgroups.Results: In 24% of samples from the AIO-PK0104 study LPS was detected; in LPS-positive patients median OS was 4.4 months, compared to 7.3 months with LPS negative tumours (HR 1.732, p = 0.010). A difference in OS was detected in 1st-line gemcitabine-treated patients (n = 71; HR 2.377, p = 0.002), but not in the non-gemcitabine treatment subgroup (n = 59; HR 1.275, p = 0.478). Within the validation cohort, the LPS positivity rate was 23%, and LPS detection was correlated with impaired OS in the gemcitabine subgroup (n = 94; HR 1.993, p = 0.008) whereas no difference in OS was observed in the non-gemcitabine subgroup (n = 19; HR 2.596, p = 0.219).Conclusions: The detection of intratumoural LPS as surrogate marker for gram-negative bacterial colonisation may serve as a negative predictor for gemcitabine efficacy in advanced PDAC.Clinical Trial Registry: The Clinical trial registry identifier is NCT00440167. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF